Go Pro

Leerink Partners' Rating of Freenome on 8/14/2026

On August 14, 2026, Leerink Partners updated its outlook on Freenome (NASDAQ:FRNM) with the action "Initiated Coverage", setting a "Outperform" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Leerink Partners

DateCompanyAction
8/14/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Initiated Coverage
8/12/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Upgrade
8/11/2026
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
Set Price Target
8/11/2026
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
Set Price Target
8/11/2026
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
Upgrade
8/7/2026
Natera, Inc. stock logo
NTRA
Natera
Set Price Target
More Ratings From Leerink Partners